Nanomedicines. A new nanotechnology platform for nanomedicines from; www.nanomeda.com

1. A unique platform for Nanomedicines
Lowest or No upfront price
New technology
Fastest results
Patent protection
Branded guarantee
Low solubility and bioavailability is a common but a road
blocker for many Novel drugs. Typically, companies will have
a hit and trial Approach to solve your problem with huge
upfront charges.
Introducing our newest Hybrid-Nanoengineering™
technology to fix your problem. You will not
only have product but a patent protection and a branding
for premium price of your product.
Are you still looking for the long term investment
winner for the next decade?
• Only solution to win the race
• Join us for that goal
• Multiple location to conduct your project
ABC llc.
Hybrid-Nanoengineering™
Just one statement!
We will provide you
the best product
With patent protection

2. A reliable solution for your success to resolve
solubility problem
Nanotechnology
A solution for
solubility
Services with patent protection
One platform for all
Nanoparticles for;
Join us
To
Win
Yes or No in three weeks
No charge for this work!
.
Increase bioavailability with efficacy and branding
Scalable technology
ABC llc.
USA

3. Dual
Action
Nanomedicines
Partnering
ABC’s Hybrid-Nanoengineering™
drug delivery platform generates more
commercial opportunities than we can pursue independently. Strategic partnering
is therefore a critical component of our ability to advance our novel therapeutics
programs into clinical development and onto the market.
Our objective is to selectively partner at strategic stages of the development process
while retaining select therapeutic programs to develop independently. We want to
strategically integrate our patented technology platform into the best possible
companies to insure we achieve the most rapid development of therapeutics which
utilize our base technology. This strategy will enable the Company to maximize the
number of lead compounds it can rapidly put into development as it continues to
harvest output and develop its platform to a higher degree of productivity. Meda
pursues the following types of collaborations:
Licensing and/or co-development arrangements for our clinical pipeline products and
pre-clinical drugs in development. We can collaborate to develop therapeutics from our
existing programs of both proteins/peptides and small molecules. Partners may choose
to advance these programs independently or in conjunction with us. We can take the
newly developed molecules or existing patent expired drugs and put them in our
platform to develop next generation of same drug to extent the further life the expired
patented drug.
One broken part can mean
total equipment failure. An
imaging
technology
partner
that
quickly
delivers the parts you need
is a lifesaver, sometimes
literally. But fast access
isn’t enough—replacement
parts also have to be
quality assured and cost
effective.
Make us your next partner
for nanomedicine and to
resolve your;
BIOAVAILABILITY
PROBLEM
Let us resolve together